J. McLeod

发表

Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects.

H. Zhou, T. Chen, M. Marino, 2000, British journal of clinical pharmacology.

Two Studies on Reversal of Opioid-induced Respiratory Depression by BK-channel Blocker GAL021 in Human Volunteers

A. Dahan, J. Hay, P. Okkerse, 2014, Anesthesiology.

Two Studies on Reversal of Opioid-induced Respiratory Depression by BK-channel Blocker GAL021 in Human Volunteers

A. Dahan, J. Hay, P. Okkerse, 2014, Anesthesiology.

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.

J. Nedelman, J. McLeod, J. Kalbag, 2001, Diabetes care.

Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus

D. Spratt, J. McLeod, S. Garreffa, 2000, European Journal of Clinical Pharmacology.

Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.

M. Seiberling, I. Savant, G. Krishna, 2009, Clinical therapeutics.

Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A

Yvonne S. Lin, J. Mao, Gail T Nolan, 2017, Drug metabolism reviews.

PLASMA VITAMIN D BINDING PROTEIN: PLASMA SCAVENGER FUNCTION AND ORIGIN OF CELL-SURFACE DBP.

J. Haddad, J. Nestler, J. McLeod, 1988 .

Characterization of a monoclonal antibody to human serum vitamin D binding protein (Gc globulin): recognition of an epitope hidden in membranes of circulating monocytes.

J. Haddad, J. McLeod, M. A. Kowalski, 1986, Endocrinology.

Vitamin D binding protein sequesters monomeric actin in the circulation of the rat.

J. Haddad, J. McLeod, K. D. Harper, 1987, The Journal of clinical investigation.

Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity

Naidong Weng, U. Diczfalusy, B. Dean, 2016, The AAPS Journal.

Effects of oral posaconazole on the pharmacokinetics of sirolimus

M. Seiberling, G. Krishna, M. Martinho, 2009, Current medical research and opinion.

Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentae.

J. Strauss, J. Haddad, J. Nestler, 1987, Endocrinology.

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

G. Sunkara, Yibin Wang, J. McLeod, 2004, European Journal of Clinical Pharmacology.

GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers.

S. Peng, J. McLeod, S. Dax, 2014, British journal of anaesthesia.

Respiratory stimulant drugs in the post-operative setting

J. McLeod, F. Golder, M. Hewitt, 2013, Respiratory Physiology & Neurobiology.

Effects of Oral Posaconazole on the Pharmacokinetics of Atazanavir Alone and With Ritonavir or With Efavirenz in Healthy Adult Volunteers

M. Seiberling, G. Krishna, M. Martinho, 2009, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers

G. Krishna, J. McLeod, Lei Ma, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment

R. Preston, E. O'Mara, G. Krishna, 2010, Current medical research and opinion.

Clinical Pharmacokinetics of Nateglinide

J. McLeod, 2004, Clinical pharmacokinetics.

Pharmacokinetics and metabolism of nateglinide in humans.

M. Weaver, J. Mangold, L. Rodriguez, 2001, Drug metabolism and disposition: the biological fate of chemicals.

The Effect of Food on the Oral Bioavailability and the Pharmacodynamic Actions of the Insulinotropic Agent Nateglinide in Healthy Subjects

B. Dunning, A. Karara, J. McLeod, 1999, Journal of clinical pharmacology.

The vitamin D-binding protein, alpha-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues.

N. Cooke, J. McLeod, 1989, The Journal of biological chemistry.

Vitamin D‐Binding Protein

N. Cooke, A. Murgia, J. McLeod, 1988 .

Syndromes of Vitamin D Resistance

J. Haddad, J. McLeod, J. Mcleod, 1997 .

Vitamin D binding protein: Genomic structure, functional domains, and mRNA expression in tissues

K. Ray, N. Cooke, Xinkang Wang, 1991, The Journal of Steroid Biochemistry and Molecular Biology.

The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective

Amy Roe, Volker Fischer, John Kao, 2003, Journal of clinical pharmacology.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Amy Roe, R Scott Obach, Volker Fischer, 2003, Drug metabolism and disposition: the biological fate of chemicals.

The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young

J. McLeod, S. Osborne, J. Campestrini, 2001, Alimentary pharmacology & therapeutics.

Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation.

G. Robertson, M. Gaskill, S. Rittig, 1993, The Journal of clinical endocrinology and metabolism.

Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity

Naidong Weng, U. Diczfalusy, B. Dean, 2016, The AAPS Journal.

Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.

S. Kahn, C. Hsu, J. Foley, 2001, The Journal of clinical endocrinology and metabolism.

Pharmacokinetics of Multiple Doses of Valsartan in Patients With Heart Failure

C. Yeh, R. Glazer, J. McLeod, 2002, Journal of cardiovascular pharmacology.

Distribution of growth hormone receptor messenger ribonucleic acid containing and lacking exon 3 in human tissues.

G. Baumann, M. Mercado, J. McLeod, 1994, The Journal of clinical endocrinology and metabolism.

Comparison of inhibition of bone resorption and escape with calcitonin and dibutyryl 3',5' cyclic adenosine monophosphate.

L. Raisz, J. McLeod, 1981, Endocrine research communications.

Effect of Meal Timing Not Critical for the Pharmacokinetics of Tegaserod (HTF 919)

Honghui Zhou, M. Guerret, H. Lau, 1999, Journal of clinical pharmacology.

Reversal of opioid‐induced respiratory depression by BK‐channel blocker GAL021: A pharmacokinetic‐pharmacodynamic modeling study in healthy volunteers

A. Dahan, J. V. van Gerven, E. Olofsen, 2015, Clinical pharmacology and therapeutics.

“Cocktail” Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science?

Honghui Zhou, Honghui Zhou, Zeen Tong, 2004, Journal of clinical pharmacology.

Effects of oral posaconazole on the pharmacokinetics of sirolimus.

M. Seiberling, G. Krishna, M. Martinho, 2009, Current medical research and opinion.

The Effects of Tegaserod (HTF 919) on the Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy Subjects

Honghui Zhou, M. Hubert, J. McLeod, 2001, Journal of clinical pharmacology.

Single‐Dose Pharmacokinetics of Nateglinide in Subjects with Hepatic Cirrhosis

K. Lasseter, J. McLeod, S. Choudhury, 2000, Journal of clinical pharmacology.

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

A. Karara, A. Pietri, J. McLeod, 2000, Diabetes care.

Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

S. Subramanian, J. McLeod, Y. Walter, 2000, The Journal of clinical endocrinology and metabolism.

The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol

G. Sunkara, J. McLeod, H. Bigler, 2004, Current medical research and opinion.

Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice

S Madani, S. Cohen, J. Fleishaker, 2010, Clinical pharmacology and therapeutics.

Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919)

F. Pommier, J. McLeod, S. Osborne, 2001, European Journal of Clinical Pharmacology.

Pharmacokinetics of Nateglinide in Renally Impaired Diabetic Patients

D. Devineni, J. McLeod, Y. Walter, 2003, Journal of clinical pharmacology.

Nateglinide, a New Mealtime Glucose Regulator

Honghui Zhou, D. Devineni, Yulia H. Walter, 2000 .

Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjects

Honghui Zhou, M. Hubert, Peiming Ma, 2000 .

Tegaserod Pharmacokinetics Are Similar in Patients with Severe Renal Insufficiency and in Healthy Subjects

S. Swan, Honghui Zhou, M. Hubert, 2003, Journal of clinical pharmacology.